Debiopharm taps Singapore expertise for epigenetic drug discovery deal
This article was originally published in Scrip
Debiopharm has entered into a basic research collaboration with the Experimental Therapeutics Centre (ETC) of Singapore's Agency for Science, Technology and Research (A*STAR), to develop oral small molecule modulators of epigenetic function.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.